Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김지은 | - |
dc.date.accessioned | 2018-03-16T06:26:00Z | - |
dc.date.available | 2018-03-16T06:26:00Z | - |
dc.date.issued | 2014-08 | - |
dc.identifier.citation | Journal of Korean medical science, 2014, 29(8), p1178 ~ 1182 | en_US |
dc.identifier.issn | 1011-8934 | - |
dc.identifier.uri | https://synapse.koreamed.org/DOIx.php?id=10.3346/jkms.2014.29.8.1178 | - |
dc.identifier.uri | http://hdl.handle.net/20.500.11754/47980 | - |
dc.description.abstract | With increase of multi-drug resistant Escherichia coli in community-acquired urinary tract infections (CA-UTI), other treatment option with a therapeutic efficacy and a low antibiotic selective pressure is necessary. In this study, we evaluated in vitro susceptibility of E. coli isolates from CA-UTI to fosfomycin (FM), nitrofurantoin (NI), temocillin (TMO) as well as trimethoprim-sulfamethoxazole (SMX), ciprofloxacin (CIP) and cefepime (FEP). The minimal inhibitory concentrations were determined by E-test or agar dilution method according to the Clinical and Laboratory Standards Institute guidelines, using 346 E. coli collected in 12 Korean hospitals from March 2010 to February 2011. FM, NI and TMO showed an excellent susceptibility profile; FM 100% (346/346), TMO 96.8% (335/346), and NI 99.4% (344/346). Conversely, resistance rates of CIP and SMX were 22% (76/346) and 29.2% (101/349), respectively. FEP still retained an activity of 98.5%. In Korea, NI and TMO in addition to FM are a good therapeutic option for uncomplicated CA-UTI, especially for lower UTI. | en_US |
dc.description.sponsorship | This work was supported by a grant of the Korea Healthcare technology R&D Project, Ministry of Health and Welfare, Republic of Korea (A084063). | en_US |
dc.language.iso | en | en_US |
dc.publisher | KOREAN ACAD MEDICAL SCIENCES, 302 75 DONG DU ICHON, DONG YONGSAN KU, SEOUL 140 031, SOUTH KOREA | en_US |
dc.subject | Community-Acquired Infections | en_US |
dc.subject | Urinary Tract | en_US |
dc.subject | Escherichia coli | en_US |
dc.subject | Fosfomycin | en_US |
dc.subject | Nitrofurantoin | en_US |
dc.subject | Temocillin | en_US |
dc.subject | Trimethoprim-Sulfamethoxazole combination | en_US |
dc.subject | Ciprofloxacin | en_US |
dc.subject | Cefepime | en_US |
dc.subject | Minimal Inhibitory Concentration | en_US |
dc.title | Susceptibility of Escherichia coli from Community-Acquired Urinary Tract Infection to Fosfomycin, Nitrofurantoin, and Temocillin in Korea | en_US |
dc.type | Article | en_US |
dc.relation.no | 8 | - |
dc.relation.volume | 29 | - |
dc.identifier.doi | 10.3346/jkms.2014.29.8.1178 | - |
dc.relation.page | 1178-1181 | - |
dc.relation.journal | JOURNAL OF KOREAN MEDICAL SCIENCE | - |
dc.contributor.googleauthor | Seo, Mi-Ran | - |
dc.contributor.googleauthor | Kim, Seong-Jong | - |
dc.contributor.googleauthor | Kim, Yeon-Jae | - |
dc.contributor.googleauthor | Kim, Ji-Eun | - |
dc.contributor.googleauthor | Choi, Tae-Yeal | - |
dc.contributor.googleauthor | Kang, Jung-Oak | - |
dc.contributor.googleauthor | Wie, Seong-Heon | - |
dc.contributor.googleauthor | Ki, Mo-Ran | - |
dc.contributor.googleauthor | Cho, Young-Kyun | - |
dc.contributor.googleauthor | Lim, Seung-Kwan | - |
dc.relation.code | 2014033608 | - |
dc.sector.campus | S | - |
dc.sector.daehak | COLLEGE OF MEDICINE[S] | - |
dc.sector.department | DEPARTMENT OF MEDICINE | - |
dc.identifier.pid | quidam76 | - |
dc.identifier.researcherID | 51963871600 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.